Overcoming Graft Rejection in Induced Pluripotent Stem Cell-Derived Inhibitory Interneurons for Drug-Resistant Epilepsy
Authors:
- Cameron P. BeaudreaultCBCameron P. Beaudreault
- Richard WangRWRichard Wang
- Carrie Rebecca MuhCMCarrie Rebecca Muh
- Ashley RosenbergARAshley Rosenberg
- Abigail FunariAFAbigail Funari
- Patty E. McGoldrickPMPatty E. McGoldrick
- Steven M. WolfSWSteven M. Wolf
- Ariel SacknovitzASAriel Sacknovitz
- Sangmi ChungSCSangmi Chung
Open Access
- 16 October 2024
- journal article
- review article
- Published by MDPI AG in Brain Sciences
- Vol. 14 (10) , 1027
Abstract
Background: Cell-based therapies for drug-resistant epilepsy using induced pluripotent stem cell-derived inhibitory interneurons are now in early-phase clinical trials, building on findings from trials in Parkinson’s disease (PD) and Huntington’s disease (HD). Graft rejection and the need for immunosuppressive therapy post-transplantation pose potential barriers to more epilepsy patients becoming potential candidates for inhibitory interneurons transplantation surgery. Objectives: The present literature review weighs the evidence for and against human leukocyte antigen (HLA)-mediated graft rejection in PD and HD and examines the potential advantages and drawbacks to five broad approaches to cell-based therapies, including autologous cell culture and transplantation, in vivo reprogramming of glial cells using viral vectors, allogeneic transplantation using off-the-shelf cell lines, transplantation using inhibitory interneurons cultured from HLA-matched cell lines, and the use of hypoimmunogenic-induced pluripotent stem cell-derived inhibitory interneurons. The impact of surgical technique and associated needle trauma on graft rejection is also discussed. Methods: Non-systematic literature review. Results: While cell-based therapies have enjoyed early successes in treating a host of central nervous system disorders, the immunologic reaction against surgical procedures and implanted materials has remained a major obstacle. Conclusions: Adapting cell-based therapies using iPSC-derived inhibitory interneurons for epilepsy surgery will similarly require surmounting the challenge of immunogenicity.Keywords
This publication has 69 references indexed in Scilit:
- Use of Recommended Neurodiagnostic Evaluation Among Patients With Drug-Resistant EpilepsyJAMA Neurology, 2024
- Generation of cerebral cortical GABAergic interneurons from pluripotent stem cellsStem Cells, 2020
- Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II TrialMovement Disorders, 2020
- Repurposing the Cord Blood Bank for Haplobanking of HLA-Homozygous iPSCs and Their Usefulness to Multiple PopulationsStem Cells, 2018
- Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study GroupEpilepsia Open, 2018
- Eliminating residual iPS cells for safety in clinical applicationProtein & Cell, 2015
- Generating Hypoimmunogenic Human Embryonic Stem Cells by the Disruption of Beta 2-MicroglobulinStem Cell Reviews and Reports, 2013
- An Efficient Nonviral Method to Generate Integration-Free Human-Induced Pluripotent Stem Cells from Cord Blood and Peripheral Blood CellsStem Cells, 2013
- Selective loss of dentate hilar interneurons contributes to reduced synaptic inhibition of granule cells in an electrical stimulation‐based animal model of temporal lobe epilepsyJournal of Comparative Neurology, 2006
- A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's diseaseAnnals of Neurology, 2003